Skip to content
← Back to ingredients

Deuruxolitinib

Also known as: Leqselvi, CTP-543

Strong EvidencePharmaceuticalAlopecia Areata

Oral JAK1/JAK2 inhibitor FDA-approved in 2024 for severe alopecia areata.

Regrowth Potential60%
Long-Term Viability75%

Mechanism of Action

Deuruxolitinib is a deuterated form of ruxolitinib that selectively inhibits JAK1 and JAK2. Deuteration improves metabolic stability and pharmacokinetic properties. Like baricitinib, it suppresses the interferon-gamma-driven autoimmune response that destroys the hair follicle immune privilege in alopecia areata.

Unlock Premium Content

Get full access to in-depth analyses, cited studies, premium articles, and AI chat.

$12/mo

View pricing